A case of immune checkpoint inhibitor-related myocarditis induced by pembrolizumab for tongue cancer-Reference-Cited by-同舟云学术

A case of immune checkpoint inhibitor-related myocarditis induced by pembrolizumab for tongue cancer

Published:2022-09-20 Issue:9 Volume:68 Page:385-391
ISSN:0021-5163
Container-title:Japanese Journal of Oral and Maxillofacial Surgery
language:en
Short-container-title:Jpn. J. Oral. Maxillofac. Surg.

Author:

TOKURA Taka-aki¹,SASAKI Takanori¹,NISHIYAMA Koyo¹,OKAMOTO Jun-ya¹,DEHARI Hironari¹,MIYAZAKI Akihiro¹

Affiliation:

1. Department of Oral Surgery, Sapporo Medical University School of Medicine

Publisher

Japanese Society of Oral and Maxillofacial Surgeons

Subject

Industrial and Manufacturing Engineering,Environmental Engineering

Link

https://www.jstage.jst.go.jp/article/jjoms/68/9/68_385/_pdf

Reference30 articles.

1. 1) Brahmer JR, Lacchettiet C, et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guide line. J Clin Oncol 36: 1714-1768, 2018.

2. 2) Mahmood SS, Fradley MG, et al : Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71: 1755-1764, 2018.

3. 3) 田尻和子，関根郁夫，他：免疫チェックポイント阻害薬と心臓有害事象．循環器医 28: 3-9, 2019.

4. 4) Atallah-Yunes SA, Kadado AJ, et al : Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol 145: 1527-1557, 2019.

5. 5) Burtness B, Harrington KJ, et al : Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study. Lancet 394: 1915-1928, 2019.